![PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast artwork](https://is3-ssl.mzstatic.com/image/thumb/Podcasts113/v4/12/35/a6/1235a6f7-320a-db51-94c0-bbcbcd171dd6/mza_3933038130939089111.jpg/100x100bb.jpg)
Lucia M. Novak, MSN, ANP-BC, BC-ADM, CDTC - The Art of Medicine: Creating Treatment Regimens With GLP-1 RAs to Reduce Cardiovascular Risks in Patients With T2DM
PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast
English - December 02, 2020 23:00 - 51 minutes - ★★★ - 4 ratingsScience cme medical education cme credits peerview insession inreview endocrinology diabetes cne Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Go online to PeerView.com/SVU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) describes shared decision-making strategies to individualize treatment and reduce cardiovascular risks in patients with T2DM using GLP-1 receptor agonists (GLP-1 RAs). Upon completion of this activity, participants should be better able to: Review the role of, current guidance, and approved indications for GLP-1 RAs in the management of T2DM, Describe the difference between primary and secondary prevention of cardiovascular events and the mechanism(s) proposed for GLP-1 RAs that may reduce cardiovascular risks in patients with T2DM, Evaluate the benefits and risks of GLP-1 RAs based on results from recent clinical trials, especially in terms of primary and secondary cardiovascular prevention, Integrate GLP-1 RAs, as appropriate and using shared decision-making, into the care of patients with T2DM.